Cantabio Pharmaceuticals Equity 2024

Cantabio Pharmaceuticals Aktienanalyse

What does Cantabio Pharmaceuticals do?

Cantabio Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company was founded in 2009 by Professor Gou-Ping Chen, an expert in protein structures and functions. Cantabio Pharmaceuticals was established specifically to address neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, which are among the largest and most prevalent diseases in the aging population. The business model of Cantabio Pharmaceuticals is based on the development of products that have been developed based on new insights in molecular research and increased understanding of neurodegenerative diseases. By collaborating with universities, research laboratories, and other industry partners, the company employs an innovation strategy to present novel solutions to the public. For its research and products, the company focuses on three main areas: - Drug discovery - the company has a variety of products in the pipeline, from discovery to clinical phases, which are strictly regulated by the FDA. - Protein and antibody manufacturing - the company uses the latest technologies to manipulate proteins to maximize their beneficial effects and optimize their potential therapeutic efficacy. - Diagnostic tools - the company also develops diagnostic tests and analysis tools for the detection of biomarkers to enable faster and more accurate diagnosis. In basic research, the company has discovered a novel class of proteins called Alpha-Synuclein inhibitors. Alpha-Synuclein is a protein that is associated with Parkinson's disease due to its overproduction and accumulation. Through experiments, Cantabio scientists have discovered substances to inhibit or even reduce its production and accumulation. These discoveries have gained significant attention in the scientific community and could contribute to important advances in understanding and overcoming brain pathologies. Cantabio Pharmaceuticals' products include a range of treatments applicable to specific diseases. One of the company's most important products is the novel drug CB2813, which targets the treatment of Alzheimer's and other neurodegenerative diseases. CB2813 represents an innovation in the treatment of Alzheimer's by combating the progression of the disease at the molecular level and strengthening the brain's biochemical protection. Another product of Cantabio Pharmaceuticals is the Alpha-Synuclein inhibitor CNS5874, which is used in Parkinson's disease. Parkinson's disease is characterized by the loss of dopamine receptors and the accumulation of Alpha-Synuclein protein. Administration of CNS5874 can reduce the accumulated Alpha-Synuclein protein in the brain regions significantly affected by the disease and promote improvement in patient behavior. Overall, Cantabio Pharmaceuticals is a leading company in the field of neurodegenerative diseases, focusing on the development of innovative treatment methods. In order to expand its pipeline and improve the available treatment options for patients, the company is constantly developing new products, some of which are already in research and clinical development. Cantabio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cantabio Pharmaceuticals's Equity

Cantabio Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cantabio Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cantabio Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cantabio Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cantabio Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cantabio Pharmaceuticals stock

What is the equity of Cantabio Pharmaceuticals this year?

Cantabio Pharmaceuticals has equity of 0 USD this year.

What was the equity of Cantabio Pharmaceuticals compared to the previous year?

The equity of Cantabio Pharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Cantabio Pharmaceuticals?

A high equity is advantageous for investors of Cantabio Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cantabio Pharmaceuticals?

A low equity can be a risk for investors of Cantabio Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cantabio Pharmaceuticals affect the company?

An increase in equity of Cantabio Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cantabio Pharmaceuticals affect the company?

A reduction in equity of Cantabio Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cantabio Pharmaceuticals?

Some factors that can affect the equity of Cantabio Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cantabio Pharmaceuticals so important for investors?

The equity of Cantabio Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cantabio Pharmaceuticals take to change the equity?

To change equity, Cantabio Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cantabio Pharmaceuticals pay?

Over the past 12 months, Cantabio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cantabio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cantabio Pharmaceuticals?

The current dividend yield of Cantabio Pharmaceuticals is .

When does Cantabio Pharmaceuticals pay dividends?

Cantabio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cantabio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cantabio Pharmaceuticals located?

Cantabio Pharmaceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Cantabio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cantabio Pharmaceuticals from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Cantabio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Cantabio Pharmaceuticals in the year 2023?

In the year 2023, Cantabio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cantabio Pharmaceuticals pay out the dividend?

The dividends of Cantabio Pharmaceuticals are distributed in USD.